ICMRA celebrates 10 years of global cooperation in regulating medicinal products

1 minute, 41 seconds Read

This year marks ten years since MHRA joined seven global regulators to establish ICMRA to address the need for stronger global cooperation and alignment in the regulation of medical products.

ICMRA’s main achievement over the past decade has been the unity of its membership throughout the Covid-19 pandemic. As the first member of the ICMRA to approve a Pfizer/BioNTech-developed COVID-19 vaccine for use in the UK, the MHRA has worked together with other members to accelerate the development and approval of COVID-19 vaccines and treatments to improve the efficiency and effectiveness of regulatory processes and decision-making. .

UK leadership on safety monitoring of Covid-19 vaccines was also shared through ICMRA and supported safe use around the world.

Over the past ten years, as a founding member of ICMRA, we have demonstrated how international collaboration can address major health challenges around the world.

Through strong collaboration across ICMRA, we are able to share our national knowledge to make a global impact, support streamlined regulatory processes and ensure access to safe and effective healthcare products for patients worldwide.”

Dr June Rain, Chief Executive of MHRA

Over the past decade, MHRA and other ICMRA members have supported the work of regulators worldwide on important milestones, from the fight against antimicrobial resistance to clinical trials, pharmacovigilance, regulatory convergence and interdependence, innovation, real-world evidence and alignment. In the global COVID-19 response.

In the coming years, MHRA will continue to support ICMRA to address current and emerging human medicines regulatory and safety challenges, strengthen collaboration and communication, and enhance the quality, safety and efficacy of medicines for the benefit of patients worldwide.

The MHRA will join its fellow ICMRA members, which now number 38, for its 10th anniversary at its annual summit and plenary in Melbourne on 13-16 November.

During the summit, the MHRA will participate in discussions on key global regulatory issues and challenges, including the use of artificial intelligence and machine learning, the evolution of clinical trials and advanced medical products based on gene, cell or tissue engineering.

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *

Best Romantic Places To Propose In the World ​Jr Mehmood’s Top Performances: Ghar Ghar Ki Kahani, Aap Ki Kasam And More ​ Most Beautiful Bioluminescent Beaches in The World Health Benefits Of Curry Leaves Benefits Of Amla For Hair Growth